Viking Therapeutics, Inc
Market Cap
3.4B
Short interest (May 15)
19.2%
Net Short (Jun 03 ): 0.0%
Borrow Fee
0.31%
↑ 14.1%
Available Shares
900K
↓ 26.2%
Price Chart
Company Overview
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.